EGFR-TKIs, such as erlotinib, have shown high response rates in patients with non-small cell lung cancer and activating variants in the intracellular EGFR kinase domain [61], and may represent a potential therapeutic option for our patients carrying EGFR GVs with glioblastomas expressing Tyr1068-phosphorylated EGFR, which was associated with erlotinib sensitivity in preclinical lung cancer models [69]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.